Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · •Neoadjuvant chemotherapy is the preferred approach to treat stage II or III TNBC. •The addition of pembrolizumab to taxane-platinum–based chemotherapy followed by an anthracycline significantly increased pathologic complete response (pCR) rates and improved event-free survival in early-stage high-risk TNBC.
The addition of immunotherapy to chemotherapy for the treatment of patients with early stage TNBC in the (neo) adjuvant setting per the pivotal KEYNOTE 522 significantly improved pCR rates.
14 Ιουν 2019 · The BL1-TNBCs respond to identical neoadjuvant chemotherapy with anthracyclines and taxanes with the highest rate of pathological complete remissions (pCR) of up to 50%. The pCR rate of the other subtypes is to some extent far lower 12 , 13 .
18 Ιαν 2024 · In this exploratory study, we quantified the serum levels of 69 different cytokines in 61 patients with operable TNBC treated with neoadjuvant chemotherapy. Blood samples were collected in a...
16 Αυγ 2024 · In patients with TNBC, this study demonstrated that early clearance of ctDNA, but not CTCs, at mid-NAC treatment was associated with a higher rate of pCR. Additionally, ctDNA positivity at mid-treatment was a significant prognostic marker for reduced OS and RFS.
9 Νοε 2021 · Triple-negative breast cancer (TNBC) is a biologically and clinically heterogeneous disease, which has long been considered to present a major unmet need due to its aggressive behaviour and poor...
Chemotherapy performance in TNBC is also influenced by the immune response created against the tumor cells that die during treatment. Genetic and epigenetic modifications of TNBC aid tumor-associated antigens in developing resistance to the immune system response.
